**FOI Ref: 6478**

**Category(ies): Clinical - Drugs Clinical - Service Activity**

**Subject: Patients Treated by the Gastro Department and Orthopaedics**

**Date Received: 06/07/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?
 | 55 |
| 1. Of these five, how many of each received the following products:
	* Adalimumab (Humira)
	* Adalimumab Biosimilar
	* Etanercept (Enbrel)
	* Etanercept Biosimilar
	* Infliximab (Remicade)
	* Infliximab biosimilar
	* Golimumab (Simponi)
	* Tofacitinib (Xeljanz)
	* Ustekinumab (Stelara)
	* Vedolizumab (Entyvio)
	* Filgotinib (Jyseleca)
	* Abatacept (Orencia)
	* Baricitinib (Olumiant)
	* Certolizumab Pegol (Cimzia)
	* Rituximab (MabThera)
	* Rituximab Biosimilar
	* Tocilizumab (RoActemra)
	* Sarilumab (Kevzara)
	* Apremilast (Otezla)
	* Secukinumab (Cosentyx)
	* Isekizumab (Taltz)
	* Guselkumab (Tremfya)
	* Brodalumab (Kyntheum)
	* Risankizumab (Skyrizi)
	* Tildrakizumab (Ilumetri)
	* Upadacitinib (Rinvoq)
	* Bimekizumab (Bimzelx)
 | * Adalimumab (Humira) – 0
* Adalimumab Biosimilar – 1
* Etanercept (Enbrel) – 0
* Etanercept Biosimilar – 1
* Infliximab (Remicade) – 0
* Infliximab biosimilar – 12
* Golimumab (Simponi) – 0
* Tofacitinib (Xeljanz) – 0
* Ustekinumab (Stelara) – 0
* Vedolizumab (Entyvio) – 0
* Filgotinib (Jyseleca) – 0
* Abatacept (Orencia) – 6
* Baricitinib (Olumiant) – 1
* Certolizumab Pegol (Cimzia) – 0
* Rituximab (MabThera) – 0
* Rituximab Biosimilar – 6
* Tocilizumab (RoActemra) – 12
* Sarilumab (Kevzara) – 0
* Apremilast (Otezla) – 0
* Secukinumab (Cosentyx) – 0
* Isekizumab (Taltz) – 0
* Guselkumab (Tremfya) – 0
* Brodalumab (Kyntheum) – 0
* Risankizumab (Skyrizi) – 0
* Tildrakizumab (Ilumetri) – 0
* Upadacitinib (Rinvoq) – 0
* Bimekizumab (Bimzelx) – 0
 |
| 1. Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).
 | 0 |
| 1. Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?
	* AxSPA
	* PsA
	* PsO
 | Due to the information being stored across multiple systems and no integration of these, and no search function to enable identification of these individuals, we are unable to break down figures to that level of detail. |